Drugs / (SOF and DCV)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT04387526 Comparator | Apr 2016 → May 2017 | chronic hepatitis C virus infection | Beni-Suef University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (SOF and DCV) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04387526 ↗ |
| Known as | DCV | “This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian participants infected with HCV GT4.” NCT04387526 ↗ |
| Route | Oral | “DCV was given in a dose of 60 mg/day, orally.” NCT04387526 ↗ |